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Long-term disease-free survival in adults with T-cell acute lymphoblastic leukemia (T-ALL) remains poor, particularly after
relapse, with few available salvage options. Preclinical data suggest that inhibition of the antiapoptotic protein BCL-2 (B-cell
lymphoma 2) either alone or in combination with other agents, may be a unique therapeutic approach for the treatment of T-ALL.
We present a case of a young male with T-ALL, relapsed after allogeneic hematopoietic stem cell transplant, who achieved
a second complete remission following salvage therapy with combined venetoclax and decitabine. Assessment of measurable
residual disease by next generation sequencing showed no evidence of residual disease of a sensitivity of 1× 10−6. While the
combination of venetoclax and hypomethylating agents has shown promise in the treatment of relapsed/refractory AML, and to
our knowledge, this is the first report of this combination demonstrating clinical activity in relapsed/refractory T-ALL.
1. Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggres-
sive hematologic malignancy that accounts for approxi-
mately 25% of all adult ALL cases [1]. Despite an improved
cure rate in the pediatric ALL population, long-term disease-
free survival in adults remains poor [2]. Outcomes for pa-
tients with relapsed or refractory T-ALL are particularly
dismal, with few available therapeutic options. Recent
preclinical studies have demonstrated that inhibition of the
antiapoptotic protein BCL-2 (B-cell lymphoma 2) may be
a novel therapeutic strategy for the treatment of T-ALL,
either alone or in combination with other agents [3, 4].
Venetoclax (ABT-199) is a highly specific BCL-2 inhibitor,
currently approved for the treatment of chronic lymphocytic
leukemia. Genetic studies in T-ALL have also recognized
recurrent somatic alterations involved in DNA methylation
and posttranslational histone modifications, suggesting
a potential rationale for the combination of venetoclax and
hypomethylating agents [5].
2. Case Presentation
A 20-year-old male with no past medical history presented
with acute hypoxic respiratory failure requiring intubation.
CT scans revealed a 9.1× 7.3 cm mediastinal mass encasing
the aortic arch with extension into the lower neck resulting
in tracheal deviation. Laboratory evaluation demonstrated
a white blood cell count of 2.5×109/L with 78% blasts on
differential, hemoglobin 7.1 g/dL, and platelets 51× 109/L.
Bone marrow evaluation revealed a hypercellular marrow
with 98% blasts by morphology. By flow cytometry, blasts
expressed CD34, CD117, CD33, CD38, CD56, and CD7
and lacked expression of myeloperoxidase (MPO) and
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monocytic markers. A subset of blasts expressed low levels of
cytoplasmic CD3 although subsequent assessment by im-
munohistochemistry for CD3 was negative. 'e blasts were
negative for CD2, CD4, CD5, CD8, CD19, and cCD79a.
Cytogenetic analysis revealed 10 metaphases with a complex
karyotype including rearrangement of chromosome 4, loss
of chromosomes 12 and 13, and a rearrangement between
chromosome 13 and 1-2 unidentified markers. Molecular
testing was positive for a FLT3-ITD mutation. A fine needle
aspiration of the mediastinal mass demonstrated acute
leukemia with an immunophenotype similar to that of the
bone. T-cell gene rearrangement analysis by PCR on the
mediastinal biopsy showed no evidence of clonal T-cell gene
rearrangement. While it was difficult to assign a definite
lineage for this acute leukemia, diagnostic considerations
included acute myeloid leukemia (AML), T-ALL, and mixed
phenotype acute leukemia T/myeloid (MPAL). To meet
criteria for MPAL T/myeloid, blasts must express lineage-
defining markers for both T and myeloid lineages [6]. 'is
acute leukemia lacked MPO as well as monocytic markers
and therefore did not meet criteria for the myeloid com-
ponent of MPAL T/myeloid. While flow cytometry dem-
onstrated weak cytoplasmic CD3 on the blasts suggestive of
T-lineage differentiation, this could not be confirmed by
immunohistochemical stains. Additionally, the blasts lacked
expression of CD2, CD4, CD5, CD8, and CD1a. 'erefore,
a diagnosis of AML, NOS was initially favored.
'e patient was induced with daunorubicin in combi-
nation with high-dose cytarabine and achieved complete
remission (CR). He was consolidated with 2 cycles of high-
dose cytarabine and in light of the FLT3-ITD mutation,
sorafenib was added. Because his leukemia was considered
“poor-risk” given the extramedullary disease at presentation,
complex karyotype, and FLT3-ITD mutation, he underwent
a 7/10 haploidentical allogeneic hematopoietic cell trans-
plant (alloHCT) from his father in first remission. Condi-
tioning included fludarabine, cyclophosphamide, and low-
dose total body irradiation as per the standard Hopkins
regimen [7]. Prior to alloHCT, multiparameter flow
cytometry from the University of Washington showed no
evidence of measurable residual disease (MRD). Post-
transplant immunosuppression consisted of cyclophos-
phamide, tacrolimus, and mycophenolate mofetil. A bone
marrow biopsy and restaging PET CT at approximately day
+60 confirmed an ongoing CR and 100% donor chimerism
in the CD3, CD14/15, and CD19 compartments. For
posttransplant maintenance, he received 6 cycles azacitidine
(given daily for 5 days at 32mg/m2 in 28-day cycles)—
initiated at approximately day +100—followed by mainte-
nance sorafenib 200mg twice daily. His tacrolimus was
discontinued at approximately 6 months posttransplant with
no evidence at any point of either acute or chronic graft-
versus-host disease (GVHD).
At 13 months posttransplant, he developed progressive
neutropenia. Bone marrow evaluation revealed relapsed
leukemia with 42% blasts expressing a slightly different
immunophenotype than that of his original disease (CD117-
negative and CD5-positive). Immunohistochemical stains
on the core biopsy demonstrated that blasts were positive for
CD34, TdT, CD5, and CD7, with a small subset that was
weakly positive for CD3. Cytogenetic studies demonstrated
a complex karyotype similar to that of his original leukemia.
FLT3-ITD PCR was negative but extended mutational tes-
ting—not previously performed—revealed mutations in
FBXW7, NOTCH1, and EZH2, all of which are recurrently
mutated in T-ALL [8]. Additionally, bone marrow chime-
rism studies showed for the first time a decline in CD3 donor
chimerism from 100% to 91%.
Based on emerging data to support the use of venetoclax
in T-ALL, he began salvage therapy with venetoclax (given
daily, initially at 800mg then dose reduced to 400mg due to
the interaction with his azole for fungal prophylaxis) in
combination with decitabine (given daily for 5 days at
20mg/m2 in 28-day cycles). After 2 cycles, his peripheral
blood counts had normalized, formal CR criteria were met,
and a restaging bone marrow evaluation demonstrated no
morphologic evidence of residual leukemia. MRD asses-
sment—again performed via multiparameter flow cytometry
at the University of Washington—also showed no evidence
of persistent disease. CD3 chimerism in the bone marrow
was restored to 100% donor.
In light of the lymphoid origin of his relapsed leukemia,
next generation sequencing (NGS) was performed (Clo-
noSEQ, Adaptive Biosciences) on his relapse specimen,
identifying a dominant T-cell receptor (TCR) clone com-
prising 8.249% of total nucleated cells. We retrospectively
also assessed his original diagnostic bone marrow specimen
and found that the same TCR clone was present in 11% of
total nucleated cells. MRD assessment from a bone marrow
specimen after 2 cycles of venetoclax and decitabine—also
via ClonoSEQ—showed no detectable residual leukemia at
a sensitivity of 1 leukemic cell per 106 cells. He received
a total of 5 cycles of decitabine and venetoclax, with in-
termittent dose interruptions of venetoclax due to neu-
tropenia. He remained MRD negative via multiparameter
flow cytometry and ClonoSEQ and subsequently underwent
a second haploidentical alloHCT with fludarabine, cyclo-
phosphamide, and low-dose TBI conditioning. Decitabine
and venetoclax were discontinued shortly prior to the sec-
ond haploidentical alloHCT. He achieved full donor chi-
merism at day +18 posttransplant and continues in follow-
up.
3. Discussion
We present the case of a young male—initially diagnosed
with AML, NOS but which, in retrospect, was T-ALL—who
achieved a first complete remission following induction
chemotherapy and subsequently underwent haploidentical
alloHCT. He relapsed 13 months later with disease that was
immunophenotypically and genetically consistent with
T-ALL. He achieved a second complete remission following
2 cycles of the BCL-2 inhibitor venetoclax in combination
with the hypomethylating agent (HMA) decitabine, with no
evidence of MRD by either multiparameter flow cytometry
or NGS. He remained in remission following completion of
5 cycles of decitabine and venetoclax and subsequently
underwent a second haploidentical alloHCT. At the time of
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this writing, he remains in remission and continues in
routine posttransplant follow-up.
While the combination of venetoclax and HMAs have
shown significant promise in the treatment of
relapsed/refractory AML, to our knowledge, this is the first
report of the combination showing clinical activity in
relapsed/refractory T-ALL [9]. In vitro studies demonstrate
that some T-ALL cell lines are highly sensitive to BCL-2
inhibition [4]. One subgroup of T-ALL, early T-cell pro-
genitor (ETP) T-ALL, has historically been characterized by
treatment-resistance and high risk for relapse. Preclinical
data show that ETP T-ALL is highly BCL-2 dependent and is
sensitive to both in vitro and in vivo treatment with ven-
etoclax [10]. Early T-cell precursors have high expression of
BCL-2 but this gradually decreases during normal T-cell
differentiation. Variations in venetoclax sensitivity could
therefore be mediated in part by varying stages of differ-
entiation arrest between different subtypes of T-ALL [4].
Studies by both Bogenberger et al. [11] and Tsao et al.
[12] initially showed that the combination of azacitidine and
BCL-2 inhibition synergistically induced apoptosis in AML
cells. As monotherapy, HMAs have limited data to support
their use in ALL, although several in vitro studies suggest
that epigenetic regulation may be important in the patho-
genesis of ALL [5, 13]. Preclinical studies have shown that
promoter regions of several genes associated with biological
and prognostic significance in ALL—including the tumor
suppressor gene, FHIT (fragile histidine triad), and ERG
isoforms—are methylated in ALL and can be demethylated
with exposure to hypomethylating agents [14, 15]. 'e
limited clinical data supporting the use of HMAs in ALL
include a case report of an adult patient with concurrent
MDS and B-ALL who achieved a morphologic remission of
both ALL andMDS with azacitidine monotherapy, as well as
an older study evaluating the efficacy of single agent aza-
citidine in a variety of acute leukemias [16].'is study found
that only 2 of 23 patients with ALL achieved a CR.
In light of this patient’s prior posttransplant exposure to
HMAs, it seems unlikely that an HMA alone would have
been sufficient to induce an MRD-negative second re-
mission. Although impossible to know if the disease may
have responded to venetoclax monotherapy, we hypothesize
that—similar to what has been described in the AML set-
ting—venetoclax and HMAs are likely to work synergisti-
cally to eradicate relapsed T-ALL [17]. If proven to be
effective in larger, prospective studies, the combination of
venetoclax and HMAs would be particularly attractive in the
posttransplant relapse setting given its relatively nontoxic
profile.
4. Conclusion
'eprognosis of relapsed/refractory T-ALL is poor, with few
available therapeutic options. Preclinical studies have shown
both that BCL-2 inhibitors may be effective in T-ALL and
that epigenetic regulation plays a role in ALL pathogenesis.
In addition to the emerging data suggesting mechanistic
synergy between BCL-2 inhibition and HMA therapy in
AML, this case provides rationale for further study of
venetoclax and HMAs in relapsed T-ALL, particularly in the
posttransplant setting.
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